Bioreductive drugs as post-irradiation sensitizers: Comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9

International Journal of Radiation Oncology, Biology, Physics

Volumn 22, Issue 4, 1992, Pages 717-720

  Adams, G E ^a   Stratford, I J ^a   Edwards, H S ^a   Bremner, J C M ^a   Cole, S ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Bioreductive drugs; Hypoxia; Radiosensitization

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; CYTOTOXIN; HYDRALAZINE; MITOMYCIN C; PRODRUG; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; HYPOXIC CELL; INTRAPERITONEAL DRUG ADMINISTRATION; IRRADIATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; REDUCTION; TUMOR GROWTH;

ANIMAL; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL HYPOXIA; CELL SURVIVAL; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MICE; MICE, INBRED C3H; MISONIDAZOLE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; PRODRUGS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRIAZINES;

EID: 0026552497     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(92)90510-O     Document Type: Article

References (17)

1. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo
2. Chemotherapy of human breast-carcinoma xenografts
3. Bioreductive drugs and the selective induction of tumour hypoxia
4. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumours
5. Hypoxia targeted chemotherapy: a role for vaso-active drugs
6. Dual function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas
7. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (i.p.) administration in mice
8. Studies of the in vivo and in vitro cytotoxicity of the drug RSU 1069
9. Synthesis and evaluation of 1-(3-(2-haloethylamino)propyl)-2-nitroimidazoles as prodrugs of RSU 1069 and its analogs which are radiosensitizers and bioreductively activated cytotoxins
10. The effect of the bioreductive drugs, mitomycin C, RSU 1069 and SR 4233 on cell lines selected for their sensitivity to DNA damaging agents
11. The therapeutic response of three human tumour lines maintained in immune-suppressed mice
12. In vitro and in vivo evaluation of the indoloquinone E09 (NSC 382459) against human small cell carcinoma of the lung
13. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo
14. Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours
15. An in vivo assay to measure the viability of KHT tumour cells not previously exposed to culture conditions
16. Pharmacokinetics, distribution and metabolism of the novel bioreductive alkylating indoloquinone, E09, in rodents
17. 4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells